Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel, Carboplatin, Cetrelimab, and Niraparib in Aggressive Variant Prostate Cancer
NCT04592237Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of cetrelimab, niraparib in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2020; status: active, not recruiting.
02
Drugs
cetrelimabniraparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04592237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04592237.